You are here

Patients With Advanced Lymphoma in Remission After T-Cell Therapy

Researchers evaluate chimeric antigen receptor (CAR) T-cell treatment

In a paper published in Science Translational Medicine, researchers at the Fred Hutchinson Cancer Research Center have reported data from an early-phase study of patients with advanced non-Hodgkin’s lymphoma (NHL) who received JCAR014 (Juno Therapeutics), a chimeric antigen receptor (CAR) T-cell treatment, and chemotherapy. CAR T cells consist of the patient’s own immune cells that are genetically engineered to better-identify and kill cancer cells.

The paper reported results from the first 32 patients in a dose-finding trial of JCAR014 after a round of chemotherapy called lymphodepletion, which is designed to create a more-favorable environment for the CAR T cells to grow in the patient’s body. Key findings of the study demonstrated the importance of the choice of the lymphodepletion regimen and the effects of different doses of CAR T cells.

Half of the 18 patients who were evaluable for efficacy after receiving CAR T cells and the chemotherapy agents fludarabine and cyclophosphamide (Cy/Flu) experienced a complete response, which compared favorably with the 8% complete response rate in patients who received JCAR014 plus cyclophosphamide-based chemotherapy without fludarabine.

Dose-limiting toxicities were observed in some patients who received the highest CAR T-cell dose. The study is continuing with the intermediate CAR T-cell dose.

In patients who received Cy/Flu lymphodepletion and the intermediate dose of JCAR014, the data showed a promising early efficacy and adverse event profile. Specifically:

  • Overall response rate: 82% (9/11)
  • Complete response rate: 64% (7/11)
  • Severe cytokine release syndrome: 9% (1/11)
  • Severe neurotoxicity: 18% (2/11)

JCAR014 uses a 1:1 ratio of helper (CD4+) and killer (CD8+) CAR T cells, which join forces to kill tumor cells that produce CD19, a molecule found on the surface of many blood cancer cells, including lymphoma and leukemia. The study data suggested that with a defined one-to-one composition of cells, treatment efficacy is increased while toxic effects are minimized.

Source: Juno Therapeutics; September 7, 2016.

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM